Floatz logo

110 assets in Gastroesophageal Junction Adenocarcinoma

Therapeutic assets addressing Gastroesophageal Junction Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
pf-08046050
Gastroesophageal Junction Adenocarcinoma
Seagen, a wholly owned subsidiary of PfizerP1C (39)
pf-08046876
Gastroesophageal Junction Adenocarcinoma
PfizerP1C (39)
prt7732
Gastroesophageal Junction Adenocarcinoma
Prelude TherapeuticsP1C (39)
Torl-2-307-Adc
Gastroesophageal Junction Adenocarcinoma
TORL Biotherapeutics, LLCP1C (39)
Torl-2-307-Mab
Gastroesophageal Junction Adenocarcinoma
TORL Biotherapeutics, LLCP1C (39)
Sasanlimab
Gastroesophageal Junction Adenocarcinoma
PfizerP1D (28)
ab598
Gastroesophageal Junction Adenocarcinoma
Arcus Biosciences, Inc.P1NR ()
jr8603
Gastroesophageal Junction Adenocarcinoma
JiaRay GroupP1NR ()
nm32-2668
Gastroesophageal Junction Adenocarcinoma
Numab Therapeutics AGP1NR ()
th9619
Gastroesophageal Junction Adenocarcinoma
One-carbon Therapeutics ABP1/2NR ()
Showing 101 to 110 of 110 assets
PreviousPage 3 of 3Next